Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05105425
Other study ID # 2020-A03403-36
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 19, 2021
Est. completion date August 7, 2023

Study information

Verified date April 2024
Source Roquette Freres
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effects of daily supplementation of the NUTRIOSE® on the fecal microbiota. The hypothesis of the study is that the NUTRIOSE® is able to modulate the intestinal microbiota in a positive way, compare to a placebo, in healthy volunteers.


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date August 7, 2023
Est. primary completion date August 7, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Male volunteer, - Age between 18 and 60 years (limits included), - BMI between 18.5 and 25 kg/m² (limits included), - Having a high or a low usual fiber consumption, - With a usual normal intestinal transit. According to stool questionnaire completed between V1 and V2, mean of the 7 days of completion, maximum 3 stools / day and 5 stools/weeks minimum and with mean normal consistency (from type 3 to type 5 of the BSFS and with a tolerance of 1 to 3 stools in deviation /week) according to the investigator's opinion, - Non-smoking or with tobacco consumption < 5 cigarettes / day and agreeing to keep his smoking habits unchanged during the all duration of the study, - Weight stable within ± 5% in the last three months; - No significant change in food habits or in physical activity in the 3 months before the study and agreeing to keep these habits unchanged throughout the study; - Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination, - Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form, - Affiliated with a social security scheme - Agreeing to be registered on the national file of volunteers in biomedical research file. Exclusion Criteria: - Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder, - Suffering from gastrointestinal disorders such as celiac disease, Crohn's disease, functional constipation, irritable bowel syndrome or another gastrointestinal found to be inconsistent with the study according to the investigator, - Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, uncontrolled cardiac disease, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or another severe disorders found to be inconsistent with the conduct of the study by the investigator, - With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient, - Lactose intolerant, - Having undergone recent surgical procedure in the past 6 months or planned in the 2 months to come, - Under treatment which could significantly affect parameter(s) followed during the study according to the investigator or stopped less than 4 weeks before the V1 visit, i.e. medication with impact on intestinal transit such as anti-diarrheal, anti-spasmodic, antidepressants antibiotics, antacids, laxative, antifungal, NSAI, antivomiting, corticoids, opioids, narcotic analgesic and biliary acids chelator, and chronic hormonal treatment started less than 3 months ago (i.e. new method of hormonal contraception, thyroidal trouble treatment) - Regular intake of dietary supplements or "health foods", or products known to impact intestinal microbiota, containing or rich in prebiotic, probiotic, synbiotics, fiber, fermented milk or yogurt, kefir, ultra-yeast, vitamins and minerals or stopped less than 3 months before the inclusion visit (V1); - With a current or planned in the next 3 months specific diet (hyper or hypocaloric, vegan, vegetarian…) or stopped less than 3 months before the study, - With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator, - Consuming more than 3 standard drinks of alcoholic beverage or not agreeing to keep his alcohol consumption habits unchanged throughout the study, - Having a lifestyle deemed incompatible with the study according to the investigator including high level physical activity (defined as more than 10 hours of significant physical activity a week, walking excluded), - Taking part in another clinical trial or being in the exclusion period of a previous clinical trial, - Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros, - Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision, - Presenting a psychological or linguistic incapability to sign the informed consent, - Impossible to contact in case of emergency.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
NUTRIOSE®
After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks. They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).
GLUCIDEX® IT21 (Placebo)
After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks. They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot).

Locations

Country Name City State
France Clinical Investigation Unit of Biofortis Paris Paris
France Clinical Investigation Unit of Biofortis Saint-Herblain

Sponsors (2)

Lead Sponsor Collaborator
Roquette Freres BioFortis

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison at V3 of relative abundance of Parabacteroides genus in intestinal microbiota Assessed via Shotgun metagenomics analysis 4 weeks
Secondary Comparison at V4 of relative abundance of Parabacteroides genus in intestinal microbiota. Assessed via Shotgun metagenomics analysis 7 or 8 weeks
Secondary Comparisons at V3 and V4 of relative abundance of intestinal microbiota (Bacterial species of Parabacteroides genus, Bacteroides genus, Firmicutes phylum, the functional levels of the intestinal microbiota, ...) Assessed via Shotgun metagenomics analysis 2 weeks
Secondary Comparisons at V3 and V4 of intestinal parameters : Fecal pH Assessed via laboratory analyse (no unit) 2 weeks
Secondary Comparisons at V3 and V4 of intestinal parameters: Fecal short chain fatty acids (SCFA) Assessed via laboratory analyse (µmol/g) 2 weeks
Secondary Comparisons at V3 and V4 of intestinal parameters: Secretory immunoglobulin A in feces Assessed via laboratory analyse (mg/g) 2 weeks
Secondary The frequency of adverse events Treatment-Emergent Adverse Events (TEAE), Serious treatment-emergent adverse events (STEAE), TEAEs leading to Investigational Product (IP) discontinuation, Treatment-Emergent Adverse Reaction (TEAR) and gastro-intestinal TEAE. 7 or 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT05523687 - AME Study of [14C]-PC14586 in Healthy Male Participants Phase 1
Completed NCT02250976 - The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Phase 1
Completed NCT01948011 - Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules Phase 1
Completed NCT04086719 - An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. Phase 1
Completed NCT03686501 - D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 Early Phase 1
Terminated NCT01965301 - First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 Phase 1
Completed NCT01005160 - Drug Interaction Between CKD-501 and Metformin Phase 1
Completed NCT04534582 - Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects Phase 1
Recruiting NCT06159101 - A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects Phase 1
Completed NCT01549743 - The Pharmacokinetic Interaction Between Celecoxib and Rebamipide Phase 1
Completed NCT03532854 - Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802 Phase 1
Recruiting NCT03530228 - A Phase 1 Study of Tegoprazan on Healthy Male Volunteers Phase 1
Completed NCT01356043 - CKD-828 Drug Interaction Study (S-amlodipine) Phase 1
Completed NCT04810533 - The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers Phase 1
Completed NCT03089112 - Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501 Phase 1
Completed NCT01939639 - The Influence of Oxytocin on the Processing of Social Contact Phase 1
Completed NCT01342055 - Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male Volunteers Phase 1
Terminated NCT03863587 - Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects Phase 1
Completed NCT01606462 - Oxytocin and Social Cognition Phase 1
Completed NCT01356017 - CKD-828 Drug Interaction Study (Telmisartan) Phase 1